Items where authors include "Bayliss, R."

Article

Khan, S., Karmokar, A., Howells, L. et al. (31 more authors) (2025) An old spice with new tricks: Curcumin targets adenoma and colorectal cancer stem-like cells associated with poor survival outcomes. Cancer Letters, 629. 217885. ISSN 0304-3835

Shelford, J., Burgess, S., Rostkova, E. et al. (11 more authors) (2025) Structural characterization and inhibition of the interaction between ch-TOG and TACC3. Journal of Cell Biology, 224 (6). e202407002. ISSN 0021-9525

Sampson, J., Ju, H., Zhang, N. et al. (3 more authors) (2024) Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer. Cell Death and Disease, 15. 912. ISSN 2041-4889

Gimenez, D., Walko, M., Miles, J.A. et al. (3 more authors) (2024) Constrained TACC3 peptidomimetics for a non-canonical protein–protein interface elucidate allosteric communication in Aurora-A kinase. Chemical Science. ISSN 2041-6520

Rejnowicz, E., Batchelor, M., Leen, E. et al. (5 more authors) (2024) Exploring the dynamics and interactions of the N-myc transactivation domain through solution nuclear magnetic resonance spectroscopy. Biochemical Journal, 481 (21). pp. 1535-1556. ISSN 0264-6021

Holder, J., Miles, J.A. orcid.org/0000-0001-8839-9201, Batchelor, M. orcid.org/0000-0001-6338-5698 et al. (7 more authors) (2024) CEP192 localises mitotic Aurora-A activity bypriming its interaction with TPX2. The EMBO Journal, 43 (19). ISSN 0261-4189

Bayliss, R. orcid.org/0000-0003-0604-2773, Fry, T., Mahen, R. et al. (2 more authors) (2024) Remembering Andrew Fry (1966–2024). Journal of Cell Science, 137 (17). jcs263478. ISSN 0021-9533

Vidal, R., Leen, E., Herold, S. et al. (10 more authors) (2024) Association with TFIIIC limits MYCN localisation in hubs of active promoters and chromatin accumulation of nonphosphorylated RNA polymerase II. eLife, 13. RP94407. ISSN 2050-084X

Burgess, S.G., Paul, N.R., Richards, M.W. et al. (6 more authors) (2024) A nanobody inhibitor of Fascin-1 actin-bundling activity and filopodia formation. Open Biology, 14 (3). 230376. ISSN 2046-2441

Kim, M., Ju, H., Song, J. et al. (3 more authors) (2024) HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors. Translational Lung Cancer Research Journal, 13 (2). pp. 321-333. ISSN 2218-6751

Dawber, R.S., Gimenez, D., Batchelor, M. et al. (4 more authors) (2024) Inhibition of Aurora‐A/N‐Myc protein–protein interaction using peptidomimetics: Understanding the role of peptide cyclization. ChemBioChem, 25 (2). e202300649. ISSN 1439-4227

Bayliss, R. orcid.org/0000-0003-0604-2773, Sarnowska, E., Yeoh, S. et al. (1 more author) (2023) ALKing the flames of lung cancer immunosensitivity. Molecular Oncology, 17 (11). pp. 2218-2220. ISSN 1574-7891

Martin, H.L., Turner, A.L., Higgins, J. et al. (14 more authors) (2023) Affimer-mediated locking of p21-activated kinase 5 in an intermediate activation state results in kinase inhibition. Cell Reports, 42 (10). 113184. ISSN 2211-1247

O'Regan, L., Barone, G., Adib, R. et al. (10 more authors) (2020) EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7. Journal of Cell Science, 133 (9). jcs.241505. ISSN 0021-9533

Proceedings Paper

Holder, J., Miles, J. orcid.org/0000-0001-8839-9201, Popple, H. et al. (3 more authors) (2023) CEP192 sits at the apex of the Aurora A activation hierarchy during mitosis. In: MOLECULAR BIOLOGY OF THE CELL. Cell Bio 2023, 02-06 Dec 2023, Boston, USA. .